Biltmore Family Office LLC Buys 1,894 Johnson & Johnson (NYSE:JNJ) Shares

Biltmore Family Office LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 13.3% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,146 shares of the company’s stock after acquiring an additional 1,894 shares during the quarter. Biltmore Family Office LLC’s holdings in Johnson & Johnson were worth $2,360,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Incinalta Capital LLC bought a new stake in Johnson & Johnson in the second quarter valued at approximately $27,000. Christopher J. Hasenberg Inc bought a new stake in Johnson & Johnson in the 1st quarter valued at approximately $31,000. MFA Wealth Advisors LLC bought a new stake in Johnson & Johnson in the second quarter valued at about $43,000. Vermillion & White Wealth Management Group LLC bought a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $44,000. Finally, Grayhawk Investment Strategies Inc. boosted its holdings in Johnson & Johnson by 528.6% during the fourth quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock valued at $48,000 after acquiring an additional 259 shares during the period. 69.55% of shares are held by institutional investors.

Indoor activity

In other news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now owns 18,973 shares of the company’s stock, valued at $3,131,683.38. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.16% of the company’s shares.

The Wall Street analyst weighs in

JNJ has been the subject of several recent analyst reports. Sanford C. Bernstein boosted their price target on Johnson & Johnson from $161.00 to $171.00 in a report on Thursday, July 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $175.00 target price on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Morgan Stanley upped their target price on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. TD Securities cut their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Finally, Goldman Sachs Group cut their price target on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating on the stock in a research report on Friday, July 19th . Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.21, based on data from MarketBeat.

Check out our latest analysis of Johnson & Johnson

Johnson & Johnson trades down 0.1%

Shares of NYSE JNJ opened at $164.64 on Friday. The stock has a market cap of $396.24 billion, a P/E ratio of 10.26, a PEG ratio of 2.71 and a beta of 0.53. The company’s 50-day moving average is $159.17, and its two-hundred-day moving average is $154.00. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07, and a quick ratio of 0.85.

Johnson & Johnson (NYSE:JNJ – Get Your Free Report ) last issued its earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The firm had revenue of $22.45 billion for the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s quarterly revenue was up 4.3% year over year. In the same quarter last year, the company posted earnings of $2.80 per share. As a group, research analysts expect that Johnson & Johnson will post 10.02 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were paid a dividend of $1.24 per share. The ex-dividend date was Tuesday, August 27th. This represents a dividend of $4.96 on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio is 30.92%.

Johnson & Johnson profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures and sells various health products worldwide. The company’s Innovative Medicines segment offers products for various therapeutic areas such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis; infectious diseases including HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders and schizophrenia; oncology, such as prostate cancer, hematological malignancies, lung cancer and bladder cancer; cardiovascular and metabolic, including thrombosis, diabetes and macular degeneration; and pulmonary hypertension including pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use.

Featured stories

Want to see what other hedge funds JNJ owns? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Free Report).

Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.